Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695501 versus Humira in moderate to severe active Crohn's disease
MOH_2017-04-04_000268Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing BI 695501 with Humira to BI 695501 switch (2 arms). Primary endpoint: Clinical efficacy non-inferiority. Started Dec 2015; status: recruiting.
02
Drugs
adalimumabadalimumab-adbm
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-04-04_000268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-04_000268.